Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

BERWYN, Pa. , Aug. 24, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson's Disease (PD) has been dosed.

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson's Disease

BERWYN, Pa. , Aug. 8, 2022 /PRNewswire/ -- Annovis Bio, Inc.  (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.

Annovis Bio Announces Second Quarter 2022 Results and Provides Corporate Update

The Panel will be Moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D. BERWYN, Pa.

Annovis Bio to Participate on Alzheimer's Association International Conference Panel

Maria Maccecchini, Ph.D., Founder, President, and CEO, will be participating on a panel discussing the Systems Biology of Alzheimer's Disease moderated by Jeffrey Cummings, MD, ScD, and Krista Lanctôt, Ph.D.

Annovis Bio to Present at the Alzheimer's Association International Conference

Annovis Bio (ANVS) stock is soaring higher on Thursday following a positive update from the FDA for its buntanetap clinical trial. The post Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update appeared first on InvestorPlace.

Annovis Bio (ANVS) Stock Soars 6% on Positive FDA Update

Annovis Bio Inc (NYSE: ANVS) received notice from the FDA that the Phase 3 clinical study with buntanetap in early Parkinson's patients may proceed.  The FDA accepted the final protocol and the clinical development plan and approved using the company's new large-scale.

FDA Gives Green Signal To Annovis Bio's Parkinson's Trial With Buntanetap

FDA indicates the Company may proceed with the Phase 3 clinical study of buntanetap for the treatment of Parkinson's disease BERWYN, Pa. , July 7, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the Company received notice from the FDA that the Phase 3 clinical study in early Parkinson's patients may proceed.

Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson's Disease

Annovis Bio's Current Intellectual Property Portfolio Covers the Use of Buntanetap, the Company's Lead Compound, to Treat Neurodegenerative Diseases With this Recent Filing, the Company Seeks Protection for Buntanetap to Treat Infection-Dependent Neurological Injuries BERWYN, Pa. , June 9, 2022 /PRNewswire/ -- Annovis Bio (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today that the company submitted an international patent application under the Patent Cooperation Treaty for its drug platform buntanetap.

Annovis Bio Submits an International Patent Application to Cover the Treatment of Neurological Injuries Caused by Infections

Berwyn, Pennsylvania--(Newsfile Corp. - May 4, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced first quarter financial results for the quarter ended March 31, 2022, and provided a corporate update.Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis, commented, "we have made significant progress advancing buntanetap in Parkinson's disease and Alzheimer's disease this quarter. We received positive feedback from the U.S....

Annovis Bio Announces First Quarter 2022 Results and Provides Corporate Update

Collaboration to Develop Pharmacodynamic Biomarkers for BuntanetapBerwyn, Pennsylvania--(Newsfile Corp. - April 28, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, announced today a Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging (NIA), a part of the National Institutes of Health. Under this CRADA, NIA and Annovis will collaborate to develop pharmacodynamic biomarkers for buntanetap, focusing on isolating brain-derived extracellular vesicles (EV) containing potential biomarkers of neuronal...

Annovis Bio Announces Cooperative Research and Development Agreement (CRADA) with the National Institute on Aging

Berwyn, Pennsylvania--(Newsfile Corp. - April 11, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, is pleased to participate in World Parkinson's Day to promote greater awareness of how Parkinson's disease affects those living with the progressive disease and support research efforts to develop disease-modifying treatment options.An estimated one million people in the U.S. and more than ten million people worldwide live with Parkinson's, making...

Annovis Bio to Participate in World Parkinson's Day to Raise Awareness on the Debilitating Disease

Berwyn, Pennsylvania--(Newsfile Corp. - March 23, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th. Management will present an update on business activities. The pre-recorded presentation can be viewed during the days of the event. Sign...

Annovis Bio to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

Company Provides Update on Clinical Trial Design of Upcoming Phase 3 Clinical Trials in Parkinson's Disease on March 20, 2022Berwyn, Pennsylvania--(Newsfile Corp. - March 18, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, will present an update on the trial designs of the Company's upcoming Phase 3 trials evaluating Buntanetap in Parkinson's disease (PD) during the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™ 2022), hosted in-person in Barcelona, Spain, and virtually from March 15-20, 2022.Buntanetap (previously known as ANVS401 or Posiphen) is...

Annovis Bio Presents at International Conference on Alzheimer's & Parkinson (AD/PD 2022)

Presentation will Showcase Trial Design in Upcoming Phase 3 Trial in Parkinson's DiseaseBerwyn, Pennsylvania--(Newsfile Corp. - March 8, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will be presenting at the International Conference on Alzheimer's & Parkinson's Diseases (AD/PD™ 2022). The hybrid conference will be hosted in-person in Barcelona, Spain, and virtually from March 15-20, 2022. Maria L. Maccecchini, Ph.D., Founder, President, and CEO, and Cheng Fang, Ph.D., Senior Vice President...

Annovis Bio Announces Presentation at International Conference on Alzheimer's & Parkinson's Diseases 2022

Berwyn, Pennsylvania--(Newsfile Corp. - March 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the company will be participating in the upcoming Cowen 42nd Annual Health Care Conference.Management will present an update on business activities on Tuesday, March 8, 2022, at 12:50 p.m. ET. A live webcast of the presentation may be accessed at: https://wsw.com/webcast/cowen108/anvs/2030328. An archived replay of the webcast will...

Annovis Bio to Present at the Cowen 42nd Annual Health Care Conference

Annovis Bio Inc (NYSE: ANVS) has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD). Following the Company's submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD.

FDA Guides Annovis Bio For Two Phase 3 Buntanetap Trial In Parkinson's Disease

FDA gives guidance for two Phase 3 clinical trials of Buntanetap in Parkinson's DiseaseBerwyn, Pennsylvania--(Newsfile Corp. - January 25, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the company held a successful Type B meeting with the U.S. Food and Drug Administration (FDA) with regard to the Company's planned Phase 3 clinical studies of Buntanetap for the treatment of Parkinson's Disease (PD) as an offshoot of the Company's clinical program in Alzheimer's Disease (AD)....

Annovis Bio Announces Positive FDA Feedback for Buntanetap Phase 3 Clinical Development in Parkinson's Disease

Company Appoints Eve Damiano, MS, RAC, as Senior Vice President of Regulatory OperationsCompany Promotes Cheng Fang, Ph.D., to Senior Vice President of Research & DevelopmentBerwyn, Pennsylvania--(Newsfile Corp. - January 10, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced the appointment of Eve Damiano, MS, RAC, as its new Senior Vice President of Regulatory Operations, and the promotion of Cheng Fang, Ph.D., to...

Annovis Bio Enhances Leadership Team with Two Senior Appointments

Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the United States Adopted Names (USAN) Council has assigned the unique name "Buntanetap" for the Company's lead drug candidate ANVS401/Posiphen. Buntanetap, a translational inhibitor of neurotoxic proteins, is currently under clinical development in Alzheimer's disease (AD), Parkinson's disease (PD), and dementia in Down syndrome (AD-DS)."The USAN approval...

Annovis Bio Announces Official Unique Name Buntanetap for Lead Candidate ANVS401

Company to Conduct Virtual One-on-One Meetings During Biotech ShowcaseBerwyn, Pennsylvania--(Newsfile Corp. - January 3, 2022) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today announced that the Company will present at Biotech Showcase 2022 Virtual Conference taking place January 10-12, 2022, and the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13, 2022. Maria L. Maccecchini, Ph.D., Founder, President & Chief Executive Officer, will present an overview of Annovis.Details can be found below:Event:...

Annovis Bio to Participate in the Biotech Showcase and H.C. Wainwright Bioconnect Virtual Conferences

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative DiseasesBerwyn, Pennsylvania--(Newsfile Corp. - December 14, 2021) - Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced the publication of ANVS401's mode of action in the peer-reviewed journal Pharmaceutics with the manuscript titled "Posiphen Reduces the Levels of Huntingtin Protein through Translation Suppression".ANVS401 (Posiphen) is an oral molecule that was shown to inhibit APP and α-Syn protein...

Annovis Bio Announces Publication of ANVS401 Mechanism of Action in Peer-Reviewed Pharmaceutics

Trading to begin November 18, 2021 with current ticker "ANVS"Berwyn, Pennsylvania--(Newsfile Corp. - November 15, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today announced that the New York Stock Exchange ("NYSE") has approved the transfer of the listing of its common stock from the NYSE American LLC ("NYSE American") to the NYSE. The Company's common stock will begin trading under the symbol "ANVS"...

Annovis Bio Announces Transfer of Listing to the New York Stock Exchange

With additional data, the primary, secondary, and exploratory endpoints were met in Phase 2a studyBerwyn, Pennsylvania--(Newsfile Corp. - November 12, 2021) - Annovis Bio, Inc. (NYSE American: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative diseases, today reported new data on ANVS401 from the Company's Phase 2a study during the 14th Clinical Trials on Alzheimer's Disease conference (CTAD). ANVS401 is an oral translational inhibitor of neurotoxic aggregating proteins (TINAPs) currently being developed for AD, AD in Down...

Annovis Bio Presented At The 14th Clinical Trials on Alzheimer's Disease Conference

Anavex Life Sciences

Biogen

Eli Lilly

Prothena

Cassava Sciences Inc

An Alzheimer's Bubble That Was Well & Truly Burst May Be Blowing Up Again - Here's Why

News for Annovis Bio Stock (ANVS)